Inhibrx announces positive interim results from HexAgon trial
The Phase II segment enrolled 68 patients, with 33 assigned to the combination arm and 35 to the pembrolizumab-only arm.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance